Respiratory syncytial virus (RSV) is the number one cause of hospitalization in infants, accounting for about 25% of all ...

India’s Ministry of Health has released new guidelines to help identify respiratory viral illness symptoms. Early recognition ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

RSV infections in children needing primary care cause high economic impact due to outpatient costs and parental work absences ...

The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

The US FDA has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for use in adults aged 65 and older.

Green grass means that pasture turnout is right around the corner. The to do list gets longer than the days do. Checking ...

Moderna Covid vaccine approved for those 12-64 with risk factors Moderna expects mNEXSPIKE to be ready for 2025-2026 season ...

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.